GlassScriptPhysician profile
Jennifer Bell
NPI 1659716447
$2,861.93
in general payments reported to CMS, 2019-2025
29 companies · $518 in 2025
The $518 reported for 2025 was more than what 81% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $170 · 2021: $108 · 2022: $15.94 · 2023: $1,118 · 2024: $527 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,265 · Travel and Lodging: $898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,264.60 |
| Travel and Lodging | $897.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $916.76 | 2023-2024 | Da Vinci Surgical System |
| Hologic Sales and Service, LLC | $387.42 | 2019-2025 | Aptima, Acessa Provu System |
| Aspira Women'S Health INC | $240.51 | 2021-2024 | Ova1 |
| Abbvie INC. | $238.44 | 2019-2025 | |
| Organon LLC | $144.44 | 2022-2025 | Jada System, Nexplanon |
| Astellas Pharma US INC | $135.14 | 2019-2025 | Veozah |
| Coopersurgical, INC. | $99.63 | 2019-2025 | Summit Doppler, Paragard T 380a |
| Sage Therapeutics, LLC | $88.45 | 2025 | Zurzuvae |
| Exeltis, USA INC. | $69.59 | 2024-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $63.55 | 2020-2025 | |
| Biogen, INC. | $45.43 | 2024 | Zurzuvae |
| Supernus Pharmaceuticals, INC. | $42.18 | 2025 | Qelbree |
| Smith+Nephew, INC. | $35.35 | 2025 | Pico 14 |
| Roche Diagnostics Corporation | $35.30 | 2019 | |
| Avion Pharmaceuticals | $34.49 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Applied Medical Resources Corporation | $31.68 | 2023 | |
| Millicent US INC | $31.29 | 2025 | Intrarosa, Femring, Femlyv |
| Duchesnay USA Incorporated | $28.43 | 2019 | |
| Pfizer INC. | $28.39 | 2024 | |
| Vertical Pharmaceuticals, LLC | $27.67 | 2019 | |
| Amgen INC. | $18.80 | 2020 | |
| Mayne Pharma Commercial LLC | $18.69 | 2021 | |
| Avanos Medical | $16.42 | 2019 | |
| Daiichi Sankyo INC. | $16.23 | 2019 | |
| Pharmacosmos Therapeutics INC. | $15.84 | 2021 | |
| Lupin INC. | $14.95 | 2019 | |
| Minerva Surgical, INC | $14.33 | 2024 | |
| Olympus America INC. | $11.47 | 2020 | |
| Amag Pharmaceuticals, INC. | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.